<DOC>
	<DOCNO>NCT01652261</DOCNO>
	<brief_summary>The main objective trial show doxorubicin , bleomycin , vinblastine , dacarbazine ( ABVD ) -based response-adapted therapy advanced-stage Hodgkin lymphoma , treatment intensification ( bleomycin , etoposide , adriamycin , cyclophosphamide , vincristine , procarbazine , prednisone ( BEACOPPesc ) case positive fluorodeoxyglucose ( FDG ) positron emission tomography ( PET ) compute tomography ( CT ) one cycle ABVD , non-inferior efficacy compare intensive BEACOPPesc regimen . A second objective ass prognostic value FDG-PET/CT one cycle BEACOPPesc .</brief_summary>
	<brief_title>Very Early FDG-PET/CT-response Adapted Therapy Advanced Hodgkin Lymphoma ( H11 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inclusion criterion : Previously untreated , histologically proven classical Hodgkin lymphoma Clinical stage III/IV ( Ann Arbor ) Age 1860 WHO performance 02 Adequate organ function Patients childbearing/reproductive potential use adequate birth control measure whole duration study treatment . Written inform consent accord ICH/EU Good Clinical Practice , national/local regulation Exclusion criterion : Pregnancy lactation Specific contraindication BEACOPPesc therapy , include : Poorly control diabetes mellitus HIV infection , Chronic active hepatitis B and/or hepatitis C Concomitant previous malignancy exception basal cell skin tumor , adequately treat carcinoma situ cervix cancer complete remission &gt; 5 year Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>advanced stage</keyword>
</DOC>